We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMacroGenics Inc

MacroGenics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.3 USD -0.02 ( 0.86%)
Last update at 2026-11-12T15:36:00Z
VOLUME
149194
Market Cap
257.35M

Momentum Score

…

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.27
Low
2.43
High
52 Week Price Range
1.29
Low
5.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.32
Dividend Yield
-
Revenue TTM
175.14M
Revenue Per Share
2.76
Gross Profit TTM
-1.30M
Debt / Equity
1.92
ROE
-225.85%
Net Debt
49.55M
ROCE
-31.25%
Diluted EPS TTM
-1.53

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -75.29M -66.02M -9.06M -119.76M -202.12M
Net income -74.62M -66.97M -9.06M -120.02M -190.86M
Selling general administrative 39.16M 71.05M 52.19M 58.95M 63.01M
Gross profit 106.32M 136.04M 48.97M 144.56M 72.99M
Reconciled depreciation 7.17M 7.54M 9.64M 11.87M 11.26M
Ebit -66.78M -64.91M -7.63M -133.28M -214.05M
Ebitda -59.61M -57.37M 2.02M -121.42M -202.79M
Depreciation and amortization 7.17M 7.54M 9.64M 11.87M 11.26M
Non operating income net other - - - 1.66M 0.68M
Operating income -72.84M -110.58M -168.24M -121.42M -202.79M
Other operating expenses 222.34M 258.92M 225.44M 273.36M 278.44M
Interest expense 8.51M 1.11M 1.43M 0.26M 0.68M
Tax provision -0.67M 0.94M 0.00M - -
Interest income 6.06M 9.42M 9.69M - -
Net interest income -2.45M 8.31M 8.26M - -
Income tax expense -0.67M 0.94M 9.48M 0.26M -11.26M
Total revenue 149.50M 148.34M 57.19M 151.94M 75.64M
Total operating expenses 179.16M 246.62M 217.22M 265.98M 275.79M
Cost of revenue 43.18M 12.30M 8.22M 7.38M 2.65M
Total other income expense net -2.45M 44.56M 159.19M 1.66M 0.68M
Net income from continuing ops -74.62M -66.97M -9.06M -119.76M -202.12M
Net income applicable to common shares - - - -119.76M -202.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 256.85M 261.65M 298.42M 280.47M 335.25M
Other current assets 8.74M 11.51M 9.95M 10.16M 21.17M
Total liab 201.25M 145.60M 145.81M 138.46M 95.63M
Total stockholder equity 55.59M 116.06M 152.61M 142.01M 239.62M
Deferred long term liab - - - 59.48M -
Other current liab 22.23M 29.33M 24.24M -30.48M 33.76M
Common stock 0.63M 0.63M 0.62M 0.62M 0.61M
Capital stock 0.63M 0.63M 0.62M 0.62M 0.61M
Retained earnings -1244.34M -1169.72M -1102.75M -1093.69M -973.94M
Other liab - - - 59.74M 0.26M
Other assets - -8.90M 0.00M 1.38M 335.25M
Cash 57.22M 182.84M 100.96M 108.88M 123.47M
Total current liabilities 43.12M 55.53M 56.11M 48.61M 74.58M
Current deferred revenue 10.92M 16.32M 21.65M 69.47M 20.65M
Net debt 49.55M -145.38M -66.98M -74.05M -98.00M
Short term debt 5.18M 4.86M 3.77M 4.73M 4.68M
Short long term debt total 106.76M 37.46M 33.97M 34.83M 25.47M
Other stockholder equity 1299.26M 1285.14M 1254.75M 1235.10M 1213.00M
Property plant equipment - - - 29.57M 37.68M
Total current assets 219.94M 217.49M 251.34M 222.18M 279.56M
Net tangible assets - - - 142.01M 239.62M
Short term investments 132.70M 18.83M 128.85M 45.46M 120.15M
Net receivables 13.37M 4.31M 10.37M 56.22M 10.39M
Inventory 7.91M 0.00M 1.22M 1.45M 4.39M
Accounts payable 4.79M 5.01M 6.44M 4.90M 15.50M
Accumulated other comprehensive income 0.03M 0.00M -0.01M -0.01M -0.06M
Common stock total equity - - - 0.62M 0.61M
Retained earnings total equity - - - -1093.69M -973.94M
Non currrent assets other 1.39M 10.46M 1.39M 1.38M 18.01M
Non current assets total 36.91M 53.06M 47.08M 58.29M 55.69M
Capital lease obligations 36.76M 37.46M 33.97M 34.83M 25.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -112.19M 149.30M -80.08M 74.34M -30.41M
Change to liabilities - - - -15.50M 6.52M
Total cashflows from investing activities -114.10M 149.30M -80.08M 70.72M -36.61M
Total cash from financing activities 69.51M 0.96M 150.36M 1.66M 122.78M
Change to operating activities - - - 5.03M -2.40M
Net income -74.62M -66.97M -9.06M -119.76M -202.12M
Change in cash -125.62M 81.88M -7.93M -14.59M -57.66M
Begin period cash flow 182.84M 100.96M 108.88M 123.47M 181.13M
End period cash flow 57.22M 182.84M 100.96M 108.88M 123.47M
Total cash from operating activities -81.04M -68.37M -78.20M -86.96M -143.83M
Issuance of capital stock 0.00M 0.00M 0.62M 1.08M 117.82M
Depreciation 5.52M 7.54M 9.64M 11.87M 11.26M
Other cashflows from investing activities 0.01M 40.16M 0.06M - -
Change to inventory -7.91M -2.19M 0.23M 0.06M -6.42M
Change to account receivables -9.06M 6.06M 45.85M -45.84M 12.70M
Sale purchase of stock - - -0.31M 1.08M 117.82M
Other cashflows from financing activities 69.39M -2.48M 149.35M 0.57M 4.96M
Change to netincome - - - 23.32M 25.16M
Capital expenditures 1.91M 3.71M 1.76M 3.62M 6.20M
Change receivables - - - -45.84M 12.70M
Cash flows other operating - - - 58.49M 7.47M
Cash and cash equivalents changes - - - -14.59M -57.66M
Change in working capital -28.33M 1.39M 53.32M -2.79M 20.26M
Stock based compensation 14.29M 29.44M 18.37M 20.44M 23.13M
Other non cash items 2.10M -39.78M -150.48M 3.29M 2.04M
Free cash flow -82.95M -72.08M -79.97M -90.58M -150.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MGNX
MacroGenics Inc		 -0.02
0.86%		 2.30 - 60.98 1.47 6.23 0.73 -1.54
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

MacroGenics Inc

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

9704 Medical Center Drive, Rockville, MD, United States, 20850

301 251 5172

https://www.macrogenics.com

293

Name Title Year Born
Dr. Scott Koenig M.D., Ph.D. Pres, CEO & Director 1952
Mr. James Karrels Sr. VP, CFO & Corp. Sec. 1967
Mr. Eric Blasius Risser Chief Operating Officer 1973
Dr. Thomas M. Spitznagel Ph.D. Sr. VP of Technical Operations 1967
Dr. Ezio Bonvini Sr. VP of Research & Chief Scientific Officer 1954
Dr. Christopher Shayne James M.D. VP of Investor Relations & Corp. Communications NA
Mr. Jeffrey Stuart Peters Sr. VP & Gen. Counsel 1972
Dr. Stephen L. Eck M.D., Ph.D. Sr. VP of Clinical Devel. & Chief Medical Officer 1955
Ms. Lynn Cilinski VP, Controller & Treasurer 1958
Dr. Scott Koenig M.D., Ph.D. President, CEO & Director 1952

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…